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Background: Colorectal cancer (CRC) is one of the most frequent events in oncology.
Advances in molecular understanding of the processes of carcinogenesis have shed light
on the fundamental mechanisms of tumorigenesis. Currently, knowledge of themolecular
basis of its pathogenesis is being used to improve patient care and devise more rational
therapeutics. Still, the role played by themutation patterns of mutated genes in the clinical
outcomes that patients on pharmacological treatment receive remains unclear. In this
study, we propose to analyze the different clinical outcomes and disease prognosis of
patients with stage IV CRC treated with FOLFOX chemotherapy (fluorouracil, leucovorin,
oxaliplatin) based on different Kirsten ras (KRAS) mutation patterns.
Methods: In this cohort study, 148 patients diagnosed with stage IV CRC and treated
with FOLFOX were studied between 2008 and 2013. Mutational status of KRAS was
determined. Progression-free survival (PFS) and overall survival (OS) were measured, and
all deaths were verified. Survival analysis was performed using Kaplan–Meier analysis,
comparison amonggroupswas analyzed using the log-rank test, andmultivariate analysis
was conducted using Cox proportional-hazards regression.
Results: Among a total of 148 patients, 48 (32%) had mutated KRAS, 77% at codon
12 and 23% at codon 13. The PFS was significantly worse in the mutant KRAS patients
in comparison to wild type KRAS patients (p < 0.05). The OS did not show significant
differences between the two groups. Multivariate analysis showed KRAS mutation as an
independent negative prognostic factor for PFS. Among the various subtypes of KRAS
mutation, G12D was significantly associated with a poor prognosis in PFS (p = 0.02).
Conclusion: In our population, the KRAS mutation had an adverse impact on the
prognosis for stage IV CRC patients treated with the FOLFOX regimen.
Keywords: KRAS mutation, colorectal cancer, prognosis, molecular biomarkers, clinical outcome, FOLFOX
Introduction
Colorectal cancer (CRC) is one of the most frequent causes of cancer death in industri-
alized countries, and ranks third in prevalence in the United States (Siegel et al., 2013).
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Its occurrence is increasing in many developed and developing
countries; also in China, colon cancer represents a very impor-
tant cause of morbidity and mortality (Yang et al., 2004). Even so,
mortality rates have declined as a result of improved treatment
and eﬃcient screening and surveillance.
The development of CRC is a multi-step process characterized
by the accumulation of genetic alterations. Currently, the molec-
ular basis of the disease’s pathogenesis is an active area of research,
both in order to improve patient care, and to develop more ratio-
nal therapeutics (Kim and Kim, 2014). In this context, generating
prognostic factors is a major goal in oncology (Sridharan et al.,
2014; Phipps et al., 2015).
Clinicians have reached a consensus (Benson et al., 2013) that
treatment of CRC should be a comprehensive project that con-
sists of surgery, adjuvant chemotherapy, and certain targeted
therapies. Currently, 5-FU based chemotherapy has been recog-
nized as the ﬁrst line regimen and is utilized for adjuvant and/or
neoadjuvant treatment of CRC patients. The recent incorporation
of molecularly targeted drugs (Benson et al., 2013), such as anti-
EGFR monoclonal antibodies, into the traditional 5-FU-based
chemotherapeutic regimen (FOLFOX and FOLFIRI) improves
eﬃcacy and is now a pivotal component in the treatment of
metastatic colorectal cancer (mCRC; Grothey and Allegra, 2012).
Moreover, the tumor’s mutation status, especially in the Kirsten
ras (KRAS) gene, is a predictive marker for response of anti-
EGFR antibody therapies in patients with mCRC. So, mutation
pattern G13D is associated to sensitivity to targeted therapy
with anti-EGFR and the other mutations patterns are asso-
ciated with no response of this regimen (Bokemeyer et al.,
2012).
The KRAS is member of the ras gene family (H-, K-, and
N-ras), which encodes highly similar membrane-localized G pro-
teins with molecular weights of 21 kDa (Amado et al., 2008).
All three diﬀerent known proteins are capable of binding and
hydrolyzing GTP and participate in a signal transmission path-
way from the cytoplasm to the nucleus (Christos Karapetis et al.,
2008). Members of the ras gene family have been recognized as
key targets in tumorigenesis due to their participation in control-
ling multiple pathways aﬀecting cell growth, diﬀerentiation, and
apoptosis by interacting with a series of coordinators and eﬀec-
tors (Barbacid, 1987), as an essential component of the EGFR
signaling cascade.
In particular, KRAS is involved in the pathogenesis of many
diﬀerent malignant tumors, including lung cancer, pancreatic
cancer, and colon cancer (Macara et al., 1996; Cárdenas-Ramos
et al., 2014).
Kirsten ras can acquire activating mutations in exon 2, codons
12 and 13 (Rodenhuis et al., 1987). The prevalence ofKRASmuta-
tions varies greatly amongst diﬀerent human tumors. Previous
studies support that the frequency of mutation is around 30–40%
in CRC. These results are similar across diﬀerent ethnic groups
(Sameer et al., 2009; Cárdenas-Ramos et al., 2014; Elsamany et al.,
2014).
Identifying the status of KRAS in each patient is important
in order to determine the best therapy: patients with the wild
type (WT) could receive monoclonal antibodies against EGFR
(Schubbert et al., 2007), while KRAS mutated patients have been
associated with no-response to targeted therapies and poor prog-
nosis in diﬀerent studies (De Roock et al., 2011; Dattatreya, 2013;
Douillard et al., 2013).
The objective of this study is to assess the clinical outcomes in
patients with stage IV CRC treated with FOLFOX in addition to
evaluating the ages of the patients, KRAS mutation patterns and
the primary tumor location.
Materials and Methods
Patient’s Characteristics
In this study, we designed an observational retrospective cohort
with 450 CRC patients who were diagnosed with stages II,
III, and IV. The time period of evaluation was 2008–2014.
All patients were treated with surgery and received adjuvant
FOLFOX chemotherapy based on adding or not adding a targeted
therapy, depending on the mutation status of KRAS, availability
and/or clinical status of the patient. The exclusion criteria were
the following: previous chemotherapy for CRC, previous radio-
therapy for CRC and history of other malignancy within 5 years.
From the initial population of 450, we selected 149 patients
with stage IV disease, treated with FOLFOX-4 or modiﬁed
FOLFOX-6 regimen as a ﬁrst-line, medical history data available
and born in Argentina. Adjuvant chemotherapy was planned
for a total of 12 cycles. Patients were assessed every week during
chemotherapy treatment and then at least every 6 months
during the disease free period. The post-chemotherapy period
assessment included medical history, physical examination,
measurement of carcinoembryonic antigen level, and evaluation
with computed tomography.
The information was recovered from the electronic medical
records of the Hospital Italiano de Buenos Aires. The rollection
of patient information was anonymous. The date of death of all
patients was veriﬁed.
The research protocol was reviewed and approved by
the Hospital Italiano de Buenos Aires’s institutional Ethical
Committee.
Assay to Detect Mutant KRAS
DNA Extraction
The DNA samples were obtained from macroscopically dissected
formalin-ﬁxed paraﬃn-embedded (FFPE) specimens cut into
10µm thick sections. The slides from FFPE sample were deparaf-
ﬁnized in xylene, washed in ethanol, and rehydrated. Any tissue
surrounding the tumor was carefully pared away using scalpel
under microscopic observation. The purpose of paring was to
ensure that tumor cells comprised over 70% of remaining spec-
imen. After suspension in 400 µl of 100 mM Tris-EDTA buﬀer
and proteinase K, the specimens were incubated for 3 days at
60◦C. At the end of incubation, the genomic DNA was extracted
using commercial kits (DNA Blood Mini Kit, QIAGEN) follow-
ing the manufacturer’s protocol.
PCR Amplification and Sequencing
Sequences of the KRAS oncogene in exon 2 were ampliﬁed using
the primers forward 5′ GTGTGACATGTTCTAATATAGTCA 3′
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TABLE 1 | Patient characteristics.
Variable Relative frequency (95% CI)
Sex (n = 148)
Female 66 (58–73)
Male 34 (27–41)
Age (n = 148)
<65 years 57 (49–65)
≥65 years 43 (35–51)
Tumor location (n = 148)
Right 26 (19–33)
Left 74 (67–81)
Anti-EGFR therapy (n = 148)
No 64 (56–72)
Yes 36 (28–44)
KRAS (n = 48)
WT 68 (61–75)
MT 32 (25–40)
Codon (n = 48)
12 77 (66–88)
13 23 (11–35)
CI, confidence interval; WT, wild type; MT, mutated.
and reverse 5′ GAATGGTCCTGCACCAGTAA 3′. The primers
were designed by “Primer 3” software. The PCR mixture (50 ul)
contained 0.2–0.5 µg of DNA, 2 or 1.5 mm MgCl2, 10X con-
centrated PCR-buﬀer (QIAGEN), 200 µm of deoxyribonucleo-
side triphosphates (dATP, dCTP, dGTP, dTTP), 200 nm of each
primer, and 1.25 U of HotStar Taq DNA Polymerase (QIAGEN).
Ampliﬁcation was achieved on a Veriti thermocycler (Applied
Biosystem). After HotStarTaq DNA-polymerase activation at
95◦C for 15 min, templates were denatured at 94◦C for 2 min.
This initial step was followed by 30 cycles of PCR, each compris-
ing 1 min of denaturation at 94◦C, 1 min of annealing at 58◦C,
and 1 min of extension at 72◦C. In the last cycle, the extension
step was prolonged for 10 min. PCR products were submit-
ted to electrophoresis on 3% agarose gels in Tris-acetate-EDTA
buﬀer and stained with ethidium bromide. In all cases, direct
sequencing was performed using an Applied Biosystem 3730XL
sequencer (PE Applied Biosystems) according to the manufac-
turer’s instructions on PCR products puriﬁed using a QIAGEN
gel extraction kit. We performed a second independ reaction of
PCR and sequencing in order to conﬁrm the positive results. In
all the cases both sense and antisense strands were sequenced.
Statistical Analysis
The statistical evaluation of data was performed using commer-
cially available SPSS Statistics 17.0 software. Relative frequencies
and 95% conﬁdence intervals were calculated for categorical
data. The Pearson chi-square test was used to examine whether
there was a relationship between KRAS status and patient char-
acteristics. Continuous data was expressed as mean ± standard
deviation (SD). Survival analysis was performed using Kaplan–
Meier analysis, comparison among groups was analyzed using
the log-rank test, and multivariate analysis was conducted using
Cox proportional-hazards regression. P-values < 0.05 were con-
sidered to be statistically signiﬁcant.
Results
Patient Characteristics
A total of 148 patients with mCRC were analyzed and their
baseline characteristics are summarized in Table 1. The primary
tumor location was right colon in 26%, and left colon in 74% of
patients. According to the inclusion criteria, all patients received
12 cycles of chemotherapy with the FOLFOX regimen. Forty-
eight patients (32%) of 148 had the KRAS mutations in either
codon 12 or 13. The distribution of mutations was 77% in codon
12 and 23% in codon 13. Only 36% of patients in the total
population had been treated with anti-EGFR therapy.
We observed that in our population the treatment schedule
had not been met in all patients with WT KRAS. Approximately
half of the patients (48%) with WT KRAS had not been treated
with anti-EGFR therapy. This situation occurs because of restric-
tions on imports of medicines imposed by the government. In
our country the anti-EGFR drugs do not occur, and patients often
are harmed due to withholding at customs. Unfortunately, this
deprives the best medical care available. This data is indicated in
the tables.
Prognostic Implications of KRAS Mutation
We analyzed the KRAS mutations and characteristics of patients
in the Pearson chi-square test in order to examine whether there
was a relationship between them. In this analysis no relationship
among the characteristics of the patients and the mutational sta-
tus of KRAS was observed. We included patients in this analysis
who were not treated with anti-EGFR therapy, even KRAS WT.
The data is shown in Table 2. In Table 3 the mean and median
survival data on the patients are described. The survival analysis
with the Kaplan–Meier model showed that PFS was signiﬁcantly
worse in mutated KRAS patients compared to those with WT
KRAS w (log-rank p < 0.05). The Kaplan–Meier curve is shown
in Figure 1. There was no diﬀerence in OS between patients with
TABLE 2 | Univariate analysis.
Variable KRAS status p-value
WT MT
Sex (n = 99)
Female 16 21 NS
Male 36 26
Age (n = 99)
<65 years 30 29 NS
≥65 years 22 18
Tumor location (n = 99)
Right 15 10 NS
Left 37 37
Event (n = 88)
No 10 8 NS
Yes 39 31
Contingency tables and X2 test between KRAS status and patient characteris-
tics. WT, wild type; MT, mutated, p-value, probability value from X2 test; NS, not
significant.
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TABLE 3 | Median and mean survival time.
Survival KRAS
status
Median
[months]
Mean
[months]
Progression-Free WT 14 15.3
Survival (PFS) MT 11 11.6
Overall survival (OS) WT 27 26.1
MT 24 22.0
WT, wild type; MT, mutated.
a mutation in KRAS and WT patients (Figure 2). In our study,
multivariate analysis using the Cox proportional-hazard model
showed no statistical signiﬁcance for independent variables; how-
ever, the KRAS mutation status reﬂected a borderline p-value
[p = 0.05, associated to a HR = 1.72 and a 95%CI = (0.99–2.99)]
that allows to presume the inﬂuence of this variable for explain-
ing diﬀerences in PFS (Table 4). None of the survival analyses
included patients who had been treated with anti-EGFR therapy.
The Kaplan–Meier survival analysis of individual subtypes of
KRAS mutation performed in this study showed the following
results: the G12D subtype was associated with poor progno-
sis in PFS (log-rank p = 0.02), other subtypes mutations were
not associated with diﬀerences in progression-free survival (PFS;
Figure 3; Table 5). Furthermore, when analyzing the OS of
individual subtypes of KRAS mutation, the G12S subtype was
associated with poor prognosis (log-rank p = 0.01), while no
signiﬁcant results were shown in overall survival (OS) for other
subtypes in our population The exclusion criteria were subtypes
FIGURE 1 | Kaplan–Meier curve of progression-free survival according
to mutation status of KRAS. WT, wild type; MT, mutated.
FIGURE 2 | Kaplan–Meier curve of overall survival according to
mutation status of KRAS. WT, wild type; MT, mutated.
TABLE 4 | Multivariate analysis.
Variable HR (95% CI) p-value
KRAS 1.72 (0.99–2.99) 0.05
Sex 1.23 (0.71–2.16) 0.46
Age 0.83 (0.47–1.47) 0.51
Tumor location 0.85 (0.46–1.58) 0.61
Cox regression model of PFS. HR, hazard ratio; CI, confidence interval; reference
categories: wild type, female, <65 years, right side.
of KRAS mutations present in fewer than three cases (Figure 4;
Table 6).
Discussion
Many studies indicate that KRAS and other mutated molecules
may be important prognostic factors related to disease free-
survival (Douillard et al., 2013) and OS in CRC (Samowitz et al.,
2000). Computational Biology studies that analyzed the kinet-
ics and biophysics of mutated molecules of KRAS had shown
results regarding the instability of G12D product, as well as tridi-
mensional conﬁguration similar to the WT product of the G13D
mutation (Chen et al., 2014).
The adverse prognosis of KRAS mutation on recurrence was
observed in the Quick and Simple and Reliable (QUASAR) trial,
which evaluated 5-FU-based adjuvant treatment (Hutchins et al.,
2011). Diﬀerent prognostic eﬀects of diﬀerent patterns of KRAS
mutation have been investigated in previous studies. Samowitz
et al. (2000) found the KRAS G13Dmutation was associated with
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FIGURE 3 | Kaplan–Meier curves of progression-free survival
according to KRAS mutation patterns.
TABLE 5 | Kaplan–Meier analysis of progression-free survival.
Subtype n p-value
WT 42 –
G12D 7 0.02
G12S 3 NS
G12V 12 NS
G13D 6 NS
Comparison according to KRAS subtype. WT, wild type; reference category, WT; p-
value, probability value from log-rank test; NS, not significant. Statistically significant
results shown in bold font.
a higher risk of death in a population-based cohort. Moreover, the
characterization of KRASmutational status in the chemotherapy-
alone subgroup of patients in the CRYSTAL and OPUS trials
showed that the G13D mutation is associated with worse sur-
vival (Tejpar et al., 2012). Only the G13D mutation is sensitive
to anti-EGFR monoclonal antibodies, whereas the other muta-
tion subtypes were associated with no response (De Roock et al.,
2010). In addition, another group reached the conclusion that
patients can beneﬁt from treatments with standard chemotherapy
based on oxaliplatin or irinotecan when they evaluated the role
of KRAS altogether with other mutations such as BRAF, PK3CA,
NRAS, and AKT. In our population this association was not
observed. Possibly these results present confounders like includ-
ing patients treated with monoclonal antibodies and anti-EGFR
therapies in the analysis of survival, which clearly modify survival
(Soeda et al., 2014).
On the other hand, other researchers have not found a pos-
itive association between KRAS and the prognosis of patients
(Bruera et al., 2014). In fact, the information is discordant
FIGURE 4 | Kaplan–Meier curves of overall survival according to KRAS
mutation pattern.
TABLE 6 | Kaplan–Meier analysis of global survival.
Subtype n P-value
WT 49 –
G12D 8 NS
G12S 4 0.01
G12V 13 NS
G13D 6 NS
Comparison according to KRAS subtype. WT, wild type; reference category, WT; P-
value, probability value from log-rank test; NS, not significant. Statistically significant
results shown in bold font.
between diﬀerent studies, this is observed in a comprehensive
meta-analysis (Ren et al., 2012). All these diﬀering results drove
us to establish a hypothesis about the clinical results that char-
acterize a G12D pattern, never studied before in a diﬀerential
way. For that reason it is necessary to stratify patients in the
diﬀerent stages according to the (American Joint Committee on
Cancer [AJCC], 2009) in order to generate data from a homo-
geneous population and analyze diﬀerent mutation patterns. In
this line, many groups have investigated the association between
KRAS mutations and the prognosis of patients in a deﬁned stage
of disease (Imamura et al., 2012). Lee et al. (2015) could demon-
strate an association between KRAS and the prognosis of patients
in a homogeneous study cohort of stage III patients treated with
FOLFOX. We conducted our study in the same research line.
In the present homogeneous cohort of stage IV
Argentinean patients treated with the FOLFOX regimen,
we could observe KRAS mutations associated with a high-
risk of recurrence of disease. Specially, G12D mutations
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showed a signiﬁcantly worse clinical outcome. The detrimental
eﬀect of KRAS mutations was not shown in the analysis of OS.
Only the G12S mutation pattern showed poorer survival than
the WT, but the small number of patients with this mutation
did not allow strong conclusions to be made. We also found
patients with WT KRAS status who could have beneﬁtted from
receiving anti-EGFR therapy in combination with the traditional
regimen who did not receive this therapy. The number of patients
in this group was around 50% of the WT. Although each patient
is unique and generalize is very diﬃcult, this was probably due
to regional socioeconomic factors. As already mentioned, the
anti-EGFR therapies are not produced in our country. Argentine
import policies of foreign products, along with a fragmented
health system where patients are dependent on the approval
of therapies by private health services delay the entry of drugs
into the country. Many patients can die or progress to very
advanced stages of their disease before they have access to thera-
pies. Clearly, this does not allow the optimal treatment of patients
by physicians.
Another limitation of our study was losing patients due to
inconsistent or missing information when searching or tracking
lost patients due to their transfer to other regions of the coun-
try. We did not take into account the doses of the drugs used,
at time to review the clinical records showed slight variations
between doses in diﬀerent patients. Finally, the sample size was
insuﬃcient to test the meaning of infrequent KRAS subtypes and,
more important, analyze their clinical impact in patients.
Strengths include the use of electronic medical history, as it
provides important information on how to avoid bias and apply
criteria for inclusion in the patient population studied. A database
of this type allows a quick though retrospective study that gener-
ates evidence which can be very valuable in bringing studies of
cancer patients to the bedside. This is the ﬁrst study that specif-
ically aims to evaluate the clinical impact of speciﬁc mutational
patterns contralaterally, taking into account how the treatment
modality performed, besides being the ﬁrst study of its kind
conducted on a South American population.
In summary, in this analysis of patients with mCRC treated
with the FOLFOX regimen, the KRAS mutation was indepen-
dently associated with poorer PFS. Mutation patterns of KRAS
had diﬀerent prognostic implications. Studies involving more
patients to validate these ﬁndings are expected in the future.
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